Unknown

Dataset Information

0

Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients.


ABSTRACT: Characterization of an approach to identify leukemia neoantigens arising in the context of drug resistance.We assessed whether leukemia neoantigens could be generated from drug-resistant mutations in BCR-ABL after imatinib relapse in patients with chronic myelogenous leukemia (CML).We computationally predicted that approximately 70 peptides derived from 26 BCR-ABL mutations would bind eight common alleles of MHC class I (IC(50) < 1,000 nmol/L). Seven of nine imatinib-resistant CML patients were predicted to generate at least 1 peptide that binds autologous HLA alleles. We predicted and confirmed that an E255K mutation-derived peptide would bind HLA-A3 with high affinity (IC(50) = 28 nmol/L), and showed that this peptide is endogenously processed and presented. Polyfunctional E255K-specific CD8+ T cells were detected in two imatinib-resistant HLA-A3+ CML patients concurrent with an effective anti-CML response to further therapy.Our in vitro studies support the hypothesis that leukemia-driven genetic alterations are targeted by the immune system in association with a clinical response, and suggest the possibility of immunizing relapsed patients with CML against newly acquired tumor neoantigens.

SUBMITTER: Cai A 

PROVIDER: S-EPMC3759991 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients.

Cai Ann A   Keskin Derin B DB   DeLuca David S DS   Alonso Anselmo A   Zhang Wandi W   Zhang Guang Lan GL   Hammond Naa Norkor NN   Nardi Valentina V   Stone Richard M RM   Neuberg Donna D   Sidney John J   Brusic Vladimir V   Wu Catherine J CJ  

Clinical cancer research : an official journal of the American Association for Cancer Research 20120821 20


<h4>Purpose</h4>Characterization of an approach to identify leukemia neoantigens arising in the context of drug resistance.<h4>Experimental design</h4>We assessed whether leukemia neoantigens could be generated from drug-resistant mutations in BCR-ABL after imatinib relapse in patients with chronic myelogenous leukemia (CML).<h4>Results</h4>We computationally predicted that approximately 70 peptides derived from 26 BCR-ABL mutations would bind eight common alleles of MHC class I (IC(50) < 1,000  ...[more]

Similar Datasets

| S-EPMC8758722 | biostudies-literature
| S-EPMC7352889 | biostudies-literature
| S-EPMC5450736 | biostudies-literature
| S-EPMC8654699 | biostudies-literature
| S-EPMC124303 | biostudies-literature
| S-EPMC2810991 | biostudies-literature
| S-EPMC3933093 | biostudies-literature
| S-EPMC4072521 | biostudies-literature
| S-EPMC7139888 | biostudies-literature
| S-EPMC2927857 | biostudies-literature